JP2020514282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514282A5 JP2020514282A5 JP2019534858A JP2019534858A JP2020514282A5 JP 2020514282 A5 JP2020514282 A5 JP 2020514282A5 JP 2019534858 A JP2019534858 A JP 2019534858A JP 2019534858 A JP2019534858 A JP 2019534858A JP 2020514282 A5 JP2020514282 A5 JP 2020514282A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cbd
- thc
- composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 15
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 10
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 10
- 229950011318 cannabidiol Drugs 0.000 claims 10
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 10
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 10
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 7
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 7
- 229960004242 dronabinol Drugs 0.000 claims 6
- 206010015037 epilepsy Diseases 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 235000008697 Cannabis sativa Nutrition 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008169 grapeseed oil Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022165695A JP2023001138A (ja) | 2016-12-20 | 2022-10-14 | 新規カンナビノイド組成物および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436861P | 2016-12-20 | 2016-12-20 | |
| US62/436,861 | 2016-12-20 | ||
| PCT/IB2017/001683 WO2018115962A1 (en) | 2016-12-20 | 2017-12-20 | Novel cannabinoid compositions and methods of treating pediatric epilepsy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165695A Division JP2023001138A (ja) | 2016-12-20 | 2022-10-14 | 新規カンナビノイド組成物および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514282A JP2020514282A (ja) | 2020-05-21 |
| JP2020514282A5 true JP2020514282A5 (enExample) | 2021-02-04 |
Family
ID=61028091
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534858A Pending JP2020514282A (ja) | 2016-12-20 | 2017-12-20 | 新規カンナビノイド組成物および使用方法 |
| JP2022165695A Pending JP2023001138A (ja) | 2016-12-20 | 2022-10-14 | 新規カンナビノイド組成物および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165695A Pending JP2023001138A (ja) | 2016-12-20 | 2022-10-14 | 新規カンナビノイド組成物および使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200215022A1 (enExample) |
| EP (1) | EP3558297A1 (enExample) |
| JP (2) | JP2020514282A (enExample) |
| KR (1) | KR20190099221A (enExample) |
| AU (1) | AU2017381587A1 (enExample) |
| BR (1) | BR112019012776A2 (enExample) |
| CA (1) | CA3046320A1 (enExample) |
| CL (1) | CL2019001668A1 (enExample) |
| CO (1) | CO2019006911A2 (enExample) |
| MX (1) | MX2019007496A (enExample) |
| PE (1) | PE20200338A1 (enExample) |
| WO (1) | WO2018115962A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| IL261132A (en) * | 2018-08-13 | 2018-11-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
| GB2580653A (en) * | 2019-01-21 | 2020-07-29 | Gw Res Ltd | Use of cannabinoids in the treatment of comorbidities associated with epilepsy |
| EP3931330A4 (en) | 2019-02-25 | 2023-03-15 | Ginkgo Bioworks, Inc. | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS |
| US11622956B1 (en) | 2019-06-26 | 2023-04-11 | RCR BioPharma | Compound and method for treating diseases and disorders |
| GB202009321D0 (en) | 2020-06-18 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2598922A (en) | 2020-09-18 | 2022-03-23 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CA3217137A1 (en) | 2021-04-29 | 2022-11-03 | Christopher Adair | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2023047308A1 (en) * | 2021-09-22 | 2023-03-30 | Avicanna Inc. | Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy |
| WO2023200906A1 (en) | 2022-04-12 | 2023-10-19 | Shackelford Pharma Inc. | Treatment of seizure disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1361864T3 (en) * | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| CA2970651C (en) * | 2014-12-12 | 2020-09-29 | Ojai Energetics Pbc | Microencapsulated cannabinoid compositions |
| BR112017018944A2 (en) * | 2015-03-02 | 2018-05-15 | Afgin Pharma, Llc | method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s) |
| WO2017137992A1 (en) * | 2016-02-11 | 2017-08-17 | Gelpell Ag | Oral solid cannabinoid formulations, methods for producing and using thereof |
-
2017
- 2017-12-20 US US16/471,407 patent/US20200215022A1/en not_active Abandoned
- 2017-12-20 JP JP2019534858A patent/JP2020514282A/ja active Pending
- 2017-12-20 EP EP17835701.8A patent/EP3558297A1/en not_active Withdrawn
- 2017-12-20 BR BR112019012776-3A patent/BR112019012776A2/pt not_active IP Right Cessation
- 2017-12-20 MX MX2019007496A patent/MX2019007496A/es unknown
- 2017-12-20 PE PE2019001299A patent/PE20200338A1/es unknown
- 2017-12-20 AU AU2017381587A patent/AU2017381587A1/en not_active Abandoned
- 2017-12-20 CA CA3046320A patent/CA3046320A1/en active Pending
- 2017-12-20 WO PCT/IB2017/001683 patent/WO2018115962A1/en not_active Ceased
- 2017-12-20 KR KR1020197018587A patent/KR20190099221A/ko not_active Ceased
-
2019
- 2019-06-17 CL CL2019001668A patent/CL2019001668A1/es unknown
- 2019-06-27 CO CONC2019/0006911A patent/CO2019006911A2/es unknown
-
2022
- 2022-10-14 JP JP2022165695A patent/JP2023001138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023168448A5 (enExample) | ||
| JP2023503309A5 (enExample) | ||
| JP2022180461A5 (enExample) | ||
| FI3883563T3 (fi) | Kannabidiolityyppinen kannabinoidiyhdiste | |
| JP2023503303A5 (enExample) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| EA200800056A1 (ru) | Каннабиноидный активный фармацевтический ингредиент для лекарственных форм | |
| PH12012502447A1 (en) | Tetrahydrocarboline derivative | |
| JP2016517888A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2020520963A5 (enExample) | ||
| CN103338761A (zh) | 抗癌剂所引起的周围神经病的预防或治疗剂 | |
| JP2016505050A5 (enExample) | ||
| JP2023530500A5 (enExample) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP5841903B2 (ja) | 肝障害の治療または肝機能の向上のための薬剤 | |
| CN105497091B (zh) | 一种用于抗癌的常山酮青蒿倍半萜内酯类化合物的组合物及其应用 | |
| JP2008540405A5 (enExample) | ||
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| JP2015524460A5 (enExample) | ||
| RU2011129815A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| NZ724678A (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| CN105078944A (zh) | Isopaucifloral F在制备抗骨质疏松药物中的用途 | |
| JP2015515971A5 (enExample) | ||
| CN110559287A (zh) | 一种用于治疗癌症的药物组合物及其应用 |